In a phase I study, rhenium obisbemeda (186RNL)—an investigational drug developed at the University of Texas Health Science Center at San Antonio—more than doubled median survival and progression-free time, compared with standard median survival and progression rates.
UCLA scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by reprogramming aggressive cancer cells into harmless ones.
